Stock comparison
Halozyme Therapeutics
Sotera Health
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.41B
Sector
Healthcare
SHC
Sotera Health
Market cap
$4.35B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | SHC | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 51C | HALO |
| Benjamin Graham | 73B | 78B | SHC |
| Philip Fisher | 55C | 47D | HALO |
| Peter Lynch | 43D | 30F | HALO |
| Joel Greenblatt | 30F | 24F | HALO |
| Charlie Munger | 70B | 54C | HALO |
| Terry Smith | 74B | 52C | HALO |
Side-by-side metrics
| Metric | HALO | SHC |
|---|---|---|
| Market cap | $8.41B | $4.35B |
| P/E (TTM) | 24.0x | 36.9x |
| EV/EBIT | 10.2x | 16.1x |
| ROIC (TTM) | 23.65% | 7.96% |
| Gross margin | 81.24% | 55.01% |
| Net margin | 23.13% | 9.91% |
| Revenue CAGR 5y | 33.23% | 5.72% |
| EPS CAGR 5y | -1.98% | -9.92% |
| Debt / Equity | 1.0x | 3.6x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs 5.72%+83%
- EPS CAGR 5y-1.98%vs -9.92%+80%
- Debt / Equity1.0xvs 3.6x+74%
- ROIC (TTM)23.65%vs 7.96%+66%
SHC leads on
No clear edges - the other side wins or ties on every measured metric.
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.